Compare Quest Diagnostics Inc (DGX) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs FMC Corp — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while FMC Corp trades at $10.33 (market cap $1.30B). The key difference: Quest Diagnostics Inc is far larger — about 20.2× FMC Corp's market cap, and FMC Corp pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| DGX | FMC | |
|---|---|---|
Market Cap | $26.21B | $1.30B |
Sector | Health | Basic Materials |
52-Week High | $238.50 | $40.69 |
52-Week Low | $173.49 | $10.01 |
Enterprise Value | $31.97B | $5.11B |
Dividend Yield | 1.45% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
FMC Corporation (FMC) trades at $10.24, down 2.1% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows a bearish technical signal with key support at $10 and resistance at $11. Fundamentally, the company faces significant challenges with a net income margin of -84.83% and negative ROE of -91.47% for 2025, though valuation ratios like P/S of 0.4 and P/B of 0.8 appear attractive. Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submission for new herbicide technology.
The outlook remains cautious due to persistent profitability issues and revenue declines, with 2025 revenue dropping to $3.47B from $4.2B in 2024. While analyst consensus is mixed with a $11.60 price target suggesting modest upside, high debt levels and competitive pressures pose substantial risks. The company's focus on debt reduction through asset sales and external investments provides some stability, but turnaround execution is critical for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
